Biomoneta, Bangalore-based biotech startup has raised an undisclosed amount from Beyond Next Ventures, ArthaVida Ventures and IVF Specialist and angel investor, Dr Aniruddha Malpani. The funding will be utilized in development of its germicidal technology and take it to market.
The company’s ZeBox technology creates germ-free zones. Deployment of the ZeBox in hospitals, clinics, homes and offices can potentially arrest the spread of multiple infections, thereby protecting patients, healthcare workers, and the community.
Dr Malpani believes that this innovation will help reduce unnecessary deaths and is glad to be part of the venture. He said, “Hospital-acquired infections result in millions of unnecessary deaths, and Biomoneta has created an innovative solution to tackle a problem that endangers the lives of vulnerable patients all over the world.“
Biomoneta is presently working on enhancing its manufacturing capacity to meet the current market needs. Dr. Janani Venkatraman, Chief Executive of Biomoneta said in a statement, “This funding is testimony to our team’s novel approach to supporting the fight against infection. The COVID-19 pandemic has demonstrated that prevention is critical, especially when no cure or vaccine exists.“
The company believes that this investment will play a crucial part in opening up new opportunities globally. “There is a huge opportunity for growth in the space, and we believe Biomoneta will establish the standard of infection control, not only in India but also globally,” said Tsuyoshi Ito, Managing Partner and CEO, BNV, and Mayu Morishima, Executive Officer, BNV.
BNV’s investment in Biomoneta is made under the CBIH (C-CAMP – BNV Innovation Hub) program, a joint funding activity which aims to both Japanese and Indian ecosystems and economies. The investors of the biotech firm have strong faith in the potential of the company and its leadership and have stated their excitement in becoming part of this innovative technology.